TICKERNERD
Menu
ELDNELDNHealthcare · Biotechnology

ELDN Stock Forecast: Eledon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$2.25
−3.85% on the day

The 6 Wall Street analysts covering Eledon Pharmaceuticals, Inc. hold a median 12-month price target of $8 — +255.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$190.2M
Ticker Nerd rank
33 / 100
Median analyst target
$8.00
Analysts covering
6
Revenue$0.0
Operating income−$22.9M
Net income−$31.6M
Free cash flow−$22.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.0%
1M
−18.8%
YTD
+49.0%
1Y
−17.0%
From 52W high
−48.4%
From 52W low
+61.9%
$1.39
$4.36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELDN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eledon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
70
Size
68
Momentum
53
Growth
53
Issuance
37
Quality
35
Volatility
31
Value
29
Revisions
28

Accruals (70): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (28): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELDN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELDN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26ELDNHigh $12.00Median $8.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $7.00Median $8.00High $12.00

The green dot is the last close — the median target sits +255.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 July 2026Rodman & RenshawInitiatesBuy$12
18 Nov 2025GuggenheimMaintainsBuy—
18 Nov 2025GuggenheimMaintainsBuy$9.00 → $8.00
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
25 July 2025Craig-HallumInitiatesBuy—
18 June 2025HC Wainwright & Co.AssumesBuy$9.00
20 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
10 May 2024HC Wainwright & Co.ReiteratesBuy—
7 May 2024HC Wainwright & Co.MaintainsBuy—
22 Mar 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
24 Oct 2023HC Wainwright & Co.MaintainsBuy—
27 Sept 2023Noble Capital MarketsInitiatesOutperform—
22 Aug 2023Cantor FitzgeraldReiteratesOverweight—
26 May 2023HC Wainwright & Co.ReiteratesBuy—
1 June 2022SVB LeerinkMaintainsOutperform—
24 Nov 2021HC Wainwright & Co.MaintainsBuy—
27 Apr 2021SVB LeerinkMaintainsOutperform—
23 Mar 2021Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELDN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ELDN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Eledon Pharmaceuticals, Inc. returned −17.0% against +17.5% for the S&P 500, dividends included.

ELDN vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26ELDNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELDN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Eledon Pharmaceuticals, Inc. (ELDN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.7×

Cheaper than 68% of US stocks

Price / sales
—
Price / book
2.6×

Cheaper than 34% of US stocks

EV / EBITDA
−0.9×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−110.7%

Higher than 12% of US stocks

Return on assets
−39.0%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Eledon Pharmaceuticals, Inc. (ELDN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eledon Pharmaceuticals, Inc. has a market value of $190.2M and an enterprise value of $101.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$98.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$73.9M.

  • Shares outstanding: 80.9M.

  • Trailing P/E: 2.7×; forward P/E: −3.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Eledon Pharmaceuticals, Inc. employs 33 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

ELDN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELDNEledon Pharmaceuticals, Inc.$190.2M
33
SIONSionna Therapeutics, Inc.$182.5M
28
RNACCartesian Therapeutics, Inc.$185.8M
27
IVVDInvivyd, Inc.$179.1M
16
UPBUpstream Bio, Inc.$187.3M
25
YARWYarrow Bioscience, Inc.$178.4M
59
ACOGAlpha Cognition, Inc.$188.4M
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eledon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELDN news & analysis

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

GlobeNewsWire · 5 Oct 2026neutral

Eledon Pharmaceuticals announced that an oral presentation will be featured at the American Society of Nephrology Kidney Week 2026 Annual Meeting, scheduled for October 21–25, 2026, in Denver, CO.

Why it matters — The presentation gives Eledon watchers an opportunity to see company data shared with the nephrology community at a major industry conference.

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

GlobeNewsWire · 22 Sept 2026positive

Eledon presented updated long-term results from the Phase 2 BESTOW extension study at the International Congress of The Transplantation Society, showing tegoprubart-treated patients maintained higher kidney function through 24 months and experienced no rejections beyond six months post-transplant versus seven in the tacrolimus arm. The company also noted the collaboration is expected to be the subject of a Phase 3 LEGACY study planned for the fourth quarter of 2026.

Why it matters — These favorable long-term kidney function and rejection data, along with FDA Fast Track designation, support the continued development of tegoprubart in kidney transplantation for ELDN watchers.

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

GlobeNewsWire · 9 Sept 2026positive

Eledon Pharmaceuticals announced that an oral presentation on the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the International Congress of The Transplantation Society in Sydney, Australia, September 20–23, 2026.

Why it matters — A presentation of tegoprubart's long-term safety and efficacy data at a leading international transplantation congress gives investors a chance to see fresh evidence on a key pipeline candidate.

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

GlobeNewsWire · 3 Sept 2026positive

Eledon Pharmaceuticals announced it has submitted an IND to the FDA for a registrational study of tegoprubart in islet cell transplantation for type 1 diabetes, and enrolled first patients in multiple transplant programs, including an investigator-initiated islet cell study, compassionate use for tacrolimus conversion, and compassionate use in highly sensitized kidney transplant recipients. The company reaffirmed its plan to initiate the global Phase 3 LEGACY kidney transplantation trial in Q4 2026.

Why it matters — This announcement shows broad progress across Eledon's tegoprubart pipeline in both islet cell and kidney transplantation, with the company reaffirming its timeline for the Phase 3 LEGACY trial.

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 13 Aug 2026positive

Eledon Pharmaceuticals reported Q2 2026 financial results, highlighting a successful End-of-Phase 2 meeting with the FDA supporting advancement of tegoprubart into a global Phase 3 kidney transplantation trial expected to begin in late 2026, along with positive long-term data from Phase 2 BESTOW and updated islet cell transplantation trials presented at medical conferences.

Why it matters — An ELDN watcher would care because the FDA's endorsement of a Phase 3 trial for tegoprubart, combined with sustained efficacy data in kidney and islet cell transplantation, marks a pivotal step toward potential commercialization of the company's lead candidate.

FAQ

Frequently asked questions about ELDN stock

What is the ELDN stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Eledon Pharmaceuticals, Inc. have a median 12-month price target of $8, with estimates ranging from $7 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELDN stock a buy right now?

Of the 6 analysts covering Eledon Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eledon Pharmaceuticals, Inc. 33 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELDN?

As at 14 Oct 2026, Eledon Pharmaceuticals, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (70 of 100).

Will ELDN stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +255.6% from the last close, and Ticker Nerd's factor model ranks Eledon Pharmaceuticals, Inc. 33 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELDN stock forecast for 2030?

No analyst covering Eledon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $12 over the next 12 months.

How has ELDN stock performed over the past year?

Eledon Pharmaceuticals, Inc. returned -17.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eledon Pharmaceuticals, Inc. do?

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for organ and cell transplantation, autoimmune disease, and neurodegenerative conditions.

What is the latest news on ELDN?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting". Eledon Pharmaceuticals announced that an oral presentation will be featured at the American Society of Nephrology Kidney Week 2026 Annual Meeting, scheduled for October 21–25, 2026, in Denver, CO.

Company

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for organ and cell transplantation, autoimmune disease, and neurodegenerative conditions. The company’s lead product candidate, tegoprubart, is an anti-CD40L antibody designed to target the CD40L pathway, which plays a central role in immune activation and transplant rejection. Eledon is currently advancing research programs in kidney transplantation, islet cell transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Its work centers on therapies intended to protect transplanted organs, reduce rejection risk, and address serious diseases with limited treatment options. Headquartered in Irvine, California, Eledon Pharmaceuticals operates as a focused drug development company within the broader biotechnology and immunology market.

CEO Dr. David-Alexandre C. Gros M.D., Ph.D. · 33 employees · United States · https://eledon.com